ECO ANIMAL HEALTH GROUP PLC Logo

ECO ANIMAL HEALTH GROUP PLC

Develops and markets pharmaceuticals and biologicals for pig and poultry health.

EAH | IL

Overview

Corporate Details

ISIN(s):
GB0005056469 (+2 more)
LEI:
2138009XN9DJ3YP7OB55
Country:
United Kingdom
Address:
THE GRANGE, 100 HIGH STREET, N14 6BN LONDON

Description

ECO Animal Health Group is a global company specializing in the development, registration, and marketing of pharmaceutical and biological products for animal health. The company's primary focus is on improving the health, welfare, and productivity of pigs and poultry by addressing economically significant respiratory and enteric diseases. Its key product is Aivlosin®, a macrolide antibiotic also marketed as Valosin®. Through its dedicated research and development, the company creates innovative solutions, including vaccines and other pharmaceuticals, to support sustainable and safe food production. ECO Animal Health operates worldwide, leveraging a global network of distributors and direct market presence.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-22 08:20
ECOVAXXIN® MS EU marketing authorisation granted
English 17.6 KB
2025-12-18 08:25
Exercise of Share Options by Director
English 27.4 KB
2025-12-09 19:10
Holding(s) in Company
English 43.1 KB
2025-12-04 15:20
Director/PDMR Shareholding
English 23.7 KB
2025-12-01 08:25
Results for the six months ended 30 September 2025
English 379.7 KB
2025-11-20 11:00
Replacement: Notice of Results
English 15.1 KB
2025-11-20 08:25
Notice of Results
English 14.9 KB
2025-11-10 08:25
EMA Positive Opinion Received for ECOVAXXIN® MS
English 16.2 KB
2025-10-01 08:00
Head of Global R&D
English 12.1 KB
2025-09-25 16:15
Result of AGM
English 25.2 KB
2025-09-25 08:00
AGM Trading Update and Notice of Interim Results
English 14.0 KB
2025-09-01 08:00
Appointment of Joint Broker
English 13.0 KB
2025-08-29 08:00
Share Awards to Executive Directors
English 43.5 KB
2025-08-28 08:48
Posting of Annual Report and Notice of AGM
English 12.9 KB
2025-08-21 13:29
Result of General Meeting
English 12.4 KB

Automate Your Workflow. Get a real-time feed of all ECO ANIMAL HEALTH GROUP PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ECO ANIMAL HEALTH GROUP PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ECO ANIMAL HEALTH GROUP PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celltrion, Inc. Logo
Biopharmaceutical firm developing biosimilars for autoimmune diseases and oncology.
South Korea
068270
Celltrion Pharm Inc. Logo
Manufactures and supplies chemical pharmaceuticals and biosimilar products.
South Korea
068760
Develops and manufactures medical devices, tissue grafts, and advanced biologics.
South Korea
049180
Celon Pharma S.A. Logo
An integrated pharmaceutical company researching and manufacturing modern drugs.
Poland
CLN
Celularity Inc Logo
Develops allogeneic cell therapies and biomaterials from the human placenta.
United States of America
CELU
Centessa Pharmaceuticals plc Logo
Clinical-stage pharmaceutical company developing medicines for unmet medical needs.
United States of America
CNTA
Century Therapeutics, Inc. Logo
Develops iPSC-derived allogeneic cell therapies for cancer and autoimmune diseases.
United States of America
IPSC
Cereno Scientific AB Logo
Clinical-stage biotech developing drugs for rare cardiovascular & pulmonary diseases.
Sweden
CRNO
CERO THERAPEUTICS HOLDINGS, INC. Logo
Immunotherapy company developing engineered T cell therapeutics for cancer treatment.
United States of America
CERO
CERUS CORP Logo
Develops pathogen inactivation technology to reduce transfusion-transmitted infections.
United States of America
CERS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.